{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T05:07:57Z","timestamp":1694840877618},"reference-count":50,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.3892\/ol.2016.4529","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T12:45:43Z","timestamp":1462452343000},"page":"4123-4130","source":"Crossref","is-referenced-by-count":3,"title":["Arsenic induced complete remission in a refractory T-ALL patient with a distinct T-cell clonal evolution without molecular complete remission: A case report"],"prefix":"10.3892","volume":"11","author":[{"given":"SUIJING","family":"WU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LING","family":"XU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIN","family":"HUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SUXIA","family":"GENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YAN","family":"XU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHAOHUA","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LIJIAN","family":"YANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIULI","family":"WU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JANYU","family":"WENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIN","family":"DU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YANGQIU","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"key20180108095827_b1-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J Clin Invest"},{"key":"key20180108095827_b2-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20180108095827_b3-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.biocel.2014.04.015","article-title":"The epigenetic landscape of T-cell acute lymphoblastic leukemia","volume":"53","author":"Van der Meulen","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"key20180108095827_b4-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/leu.2013.366","article-title":"Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia","volume":"28","author":"Koyama","year":"2014","journal-title":"Leukemia"},{"key":"key20180108095827_b5-ol-0-0-4529","first-page":"1105","article-title":"A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia","volume":"91","author":"Litzow","year":"2006","journal-title":"Haematologica"},{"key":"key20180108095827_b6-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2006-12-060970","article-title":"Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway","volume":"110","author":"Bornhauser","year":"2007","journal-title":"Blood"},{"key":"key20180108095827_b7-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.leukres.2006.06.021","article-title":"Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1","volume":"31","author":"Qian","year":"2007","journal-title":"Leuk Res"},{"key":"key20180108095827_b8-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00280-003-0629-5","article-title":"Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3","volume":"52","author":"Hu","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108095827_b9-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.4161\/cbt.6.8.4381","article-title":"Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells","volume":"6","author":"Jiao","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"key20180108095827_b10-ol-0-0-4529","first-page":"75","article-title":"Notch signaling during human T cell development","volume":"360","author":"Taghon","year":"2012","journal-title":"Curr Top Microbiol Immunol"},{"key":"key20180108095827_b11-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/dna.2013.2199","article-title":"The TCR \u03b3\u03b4 repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant V\u03b41 and V\u03b42 T cells","volume":"33","author":"Zheng","year":"2014","journal-title":"DNA Cell Biol"},{"key":"key20180108095827_b12-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1476-4598-12-73","article-title":"The evolution of malignant and reactive \u03b3\u03b4+T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation","volume":"12","author":"Chen","year":"2013","journal-title":"Mol Cancer"},{"key":"key20180108095827_b13-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V98.1.165","article-title":"Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations","volume":"98","author":"Langerak","year":"2001","journal-title":"Blood"},{"key":"key20180108095827_b14-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2162-3619-2-14","article-title":"Donor V\u03b41+ \u03b3\u03b4 T cells expand after allogeneic hematopoietic stem cell transplantation and show reactivity against CMV-infected cells but not against progressing B-CLL","volume":"2","author":"Prinz","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"key20180108095827_b15-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/sj.leu.2400887","article-title":"Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations","volume":"11","author":"Langerak","year":"1997","journal-title":"Leukemia"},{"key":"key20180108095827_b16-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","article-title":"Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study","volume":"16","author":"Takeuchi","year":"2002","journal-title":"Leukemia"},{"key":"key20180108095827_b17-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"key20180108095827_b18-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.trim.2007.05.011","article-title":"TRAV and TRBV repertoire, clonality and the proliferative history of umbilical cord blood T-cells","volume":"18","author":"Li","year":"2007","journal-title":"Transpl Immunol"},{"key":"key20180108095827_b19-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.trim.2008.10.010","article-title":"TRGV and TRDV repertoire distribution and clonality of T cells from umbilical cord blood","volume":"20","author":"Li","year":"2009","journal-title":"Transpl Immunol"},{"key":"key20180108095827_b20-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood.V96.2.640","article-title":"High detection rate of T-cell receptor beta chain rearrangements in T-cell lymphoproliferations by family specific polymerase chain reaction in combination with the GeneScan technique and DNA sequencing","volume":"96","author":"Assaf","year":"2000","journal-title":"Blood"},{"key":"key20180108095827_b21-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.4049\/jimmunol.152.10.5109","article-title":"Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status","volume":"152","author":"Gorski","year":"1994","journal-title":"J Immunol"},{"key":"key20180108095827_b22-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20180108095827_b23-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/10428190400019966","article-title":"In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha","volume":"46","author":"Mahieux","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"key20180108095827_b24-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","article-title":"Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes","volume":"24","author":"Schiller","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108095827_b25-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2005.03.9503","article-title":"Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study","volume":"24","author":"Vey","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108095827_b26-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha\/PML proteins","volume":"88","author":"Chen","year":"1996","journal-title":"Blood"},{"key":"key20180108095827_b27-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1756-8722-5-53","article-title":"Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: An ex-vivo study","volume":"5","author":"Galimberti","year":"2012","journal-title":"J Hematol Oncol"},{"key":"key20180108095827_b28-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1756-8722-3-28","article-title":"Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells","volume":"3","author":"Yedjou","year":"2010","journal-title":"J Hematol Oncol"},{"key":"key20180108095827_b29-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1080\/10428190412331272686","article-title":"Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: From bench to bedside","volume":"45","author":"Rojewski","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"key20180108095827_b30-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1182\/blood-2002-04-1154","article-title":"Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis","volume":"102","author":"Mathas","year":"2003","journal-title":"Blood"},{"key":"key20180108095827_b31-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-9966-33-42","article-title":"Arsenic trioxide induces oxidative stress, DNA damage and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells","volume":"33","author":"Kumar","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"key20180108095827_b32-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0301-472X(99)00014-4","article-title":"Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines","volume":"27","author":"Lu","year":"1999","journal-title":"Exp Hematol"},{"key":"key20180108095827_b33-ol-0-0-4529","first-page":"1041","article-title":"Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients","volume":"59","author":"Rousselot","year":"1999","journal-title":"Cancer Res"},{"key":"key20180108095827_b34-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1046\/j.1365-2141.1998.00869.x","article-title":"Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of Bcl-2 protein","volume":"102","author":"Akao","year":"1998","journal-title":"Br J Haematol"},{"key":"key20180108095827_b35-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1756-9966-28-110","article-title":"Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction","volume":"28","author":"Li","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"key20180108095827_b36-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.canlet.2014.10.025","article-title":"Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells","volume":"356","author":"Chiu","year":"2015","journal-title":"Cancer Lett"},{"key":"key20180108095827_b37-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1365-2141.1998.01068.x","article-title":"Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids","volume":"103","author":"Ishitsuka","year":"1998","journal-title":"Br J Haematol"},{"key":"key20180108095827_b38-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V93.1.278","article-title":"Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells","volume":"93","author":"Bazarbachi","year":"1999","journal-title":"Blood"},{"key":"key20180108095827_b39-ol-0-0-4529","first-page":"2849","article-title":"Arsenic-interferon-alpha-triggered apoptosis in HTLV\u2013I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation","volume":"96","author":"El-Sabban","year":"2000","journal-title":"Blood"},{"key":"key20180108095827_b40-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/10428190009058521","article-title":"Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines","volume":"37","author":"Ishitsuka","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"key20180108095827_b41-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1182\/blood.V98.13.3762","article-title":"Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage","volume":"98","author":"Mahieux","year":"2001","journal-title":"Blood"},{"key":"key20180108095827_b42-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2002-09-2986","article-title":"Arsenic\/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells","volume":"101","author":"Nasr","year":"2003","journal-title":"Blood"},{"key":"key20180108095827_b43-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3324\/haematol.10703","article-title":"Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"92","author":"Ishitsuka","year":"2007","journal-title":"Haematologica"},{"key":"key20180108095827_b44-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.thj.6200374","article-title":"Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"5","author":"Hermine","year":"2004","journal-title":"Hematol J"},{"key":"key20180108095827_b45-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-4690-10-91","article-title":"The combination of arsenic, interferon-alpha and zidovudine restores an \u2018immunocompetent-like\u2019 cytokine expression profile in patients with adult T-cell leukemia lymphoma","volume":"10","author":"Kchour","year":"2013","journal-title":"Retrovirology"},{"key":"key20180108095827_b46-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1179\/102453311X12902908411634","article-title":"Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients","volume":"16","author":"Li","year":"2011","journal-title":"Hematology"},{"key":"key20180108095827_b47-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","article-title":"The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies","volume":"6","author":"Shi","year":"2013","journal-title":"J Hematol Oncol"},{"key":"key20180108095827_b48-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","article-title":"Prof-ound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma","volume":"102","author":"Yawalkar","year":"2003","journal-title":"Blood"},{"key":"key20180108095827_b49-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2141.2009.07862.x","article-title":"Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia-a prospective study of 20 paediatric patients","volume":"147","author":"Eyrich","year":"2009","journal-title":"Br J Haematol"},{"key":"key20180108095827_b50-ol-0-0-4529","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.humimm.2011.06.015","article-title":"Characterization of the CDR3 structure of the V\u03b221 T cell clone in patients with P210 (BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia","volume":"72","author":"Zha","year":"2011","journal-title":"Hum Immunol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2016.4529\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T22:39:25Z","timestamp":1692311965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2016.4529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,5,5]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.3892\/ol.2016.4529"],"URL":"https:\/\/doi.org\/10.3892\/ol.2016.4529","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,5]]}}}